Commentary
Volume: 13 | Issue: 1 | Published: Dec 11, 2023 | Pages: 13 - 16 | DOI: 10.24911/PJNMed.175-1696399353
Genetic Perspectives on Prostate Cancer: Unveiling the Impact on Targeted Radionuclide Therapies
Authors:
Hamid Shabbir
, Muhammad Babar Imran
, Nayyar Rubab
Article Info
Authors
Hamid Shabbir
Cancer Genomics Lab, PINUM Cancer Hospital, Faisalabad, Pakistan
Muhammad Babar Imran
Department of Nuclear Medicine, PINUM Cancer Hospital, Faisalabad, Pakistan
Nayyar Rubab
Department of Nuclear Medicine, PINUM Cancer Hospital, Faisalabad, Pakistan
Publication History
Received: October 16, 2023
Accepted: November 20, 2023
Published: December 11, 2023
Abstract
Prostate cancer (PCa) is the 2nd most common malignancy in males and the leading cause of cancer-related deaths among men. In recent years, novel therapies have emerged for metastatic castration-resistant prostate cancer (mCRPC) including immunotherapy, androgen-receptor signaling inhibitors, and radio-nuclide therapies. DNA Damage Repair (DDR) genes are frequently mutated in advance PCa and are useful biomarkers for targeted therapy such as poly-ADP ribose polymerase (PARP) inhibitors. DDR gene defects may affect tissue radio-sensitivity and could serve as biomarkers for therapy with alpha and beta-emitting radionuclides. Preliminary clinical reports suggest a potential trend toward longer survival in DDR+ subjects when treated with α-emitters, however, survival benefit was not significant in patients treated with β-emitting radionuclides. A comprehensive study regarding the impact of DDR genes in prostate cancer patients treated with alpha emitters is vital.
Keywords: Prostate Cancer, Radionuclide, Genomics, Therapy, DDR
